Plus   Neg

Safran FY20 Profit Down, Proposes Dividend; Sees Higher Margin, Lower Organic Revenues In FY21

French Aerospace company Safran (SAF.PA,0IU8.L,SAFRF.PK) reported Thursday that its fiscal 2020 consolidated profit attributable to owners of the parent was 352 million euros.

Adjusted net income - Group share was 844 million euros or 1.92 euros per share, compared to last year's 2.67 billion euros or 6.13 euros per share.

Consolidated recurring operating income was 1.39 billion euros. Adjusted recurring operating income fell 56 percent from last year to 1.69 billion euros.

Group operating margin was 10.2 percent, down from 15.5 percent in the year ago period.

Consolidated revenue was 16.63 billion euros.

Adjusted revenue fell 33 percent to 16.50 billion euros from 24.64 billion euros. Revenues were down 32.5 percent on an organic basis.

In the fourth-quarter sales decreased 32.5 percent on a reported basis and 30.1 percent organically to 4.35 billion euros.

Further, the company announced that a dividend payment of 0.43 euros per share will be proposed to the shareholders' vote at the Annual General Meeting on May 26, representing a 22 percent pay-out ratio

Looking ahead for fiscal 2021, Safran expects adjusted recurring operating margin to increase above 100 basis points, at least a 300 basis points improvement versus the prior year's second half.

Adjusted revenue is expected to decrease in the low single digits in organic terms.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Johnson & Johnson's (JNJ) Covid-19 vaccine is expected to be back on track as early as this weekend as a decision is expected after the advisory panel meeting of the U.S. Centers for Disease Control and Prevention (CDC) slated on April 23, according to Dr. Anthony Fauci, the chief medical adviser to President Joe Biden. MK-4482, the experimental antiviral drug for COVID-19, showed promise to prevent and treat SARS-CoV-2 infection in hamster study, according to the scientists of National Institutes of Health or NIH. The drug significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection. MK-4482, delivered orally, is now in Phase 2 and 3 human clinical studies. Beverages giant Coca-Cola reported a 19 percent decline in profit for the second quarter from last year as a revenue growth of 5 percent and improved margins were offset by higher income taxes and interest expense. However, adjusted earnings per share and revenues topped analysts' expectations. The company also maintained its adjusted earnings and organic revenue growth outlook for fiscal 2021.
Follow RTT